5Berger M, Jorsense V, Muhauser I. Rationale for the use of insulin therapy alone as pharmacological treatment of type 2 diabetes[J] .Diabetes Came, 1999, 22(3):71-75.
6Vreges B. The impact of prandial glucose regulation in practice[J]. Diabetes Nutr Metab, 2002,15(suppl 6) :28-32.
7Wolffenbuttel BH, Landgraf R. A 1-year multi-center randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes[J]. Diabetes Care, 1999, 22(3) :463-467.
8Ichikawa K, Yamato T, Ojima K, et al. Effect of KAD- 1229, a novel hypoglycemic agent on plasma glucose levels after meal load in type 2 diabetes rats[J]. Ciin Exp Pharmacol Physiol,2002, 29(5-6) : 423-427.
9Zander M, Madsbad S, Mdsen JL, et al. Effect of 6 week course of glucagons-like peptide 1 on glycogenic control, insulin sensitivity, and β-cell function in type 2 diabetes; a parallel-group study[ J ]. Lancet, 2002, 359(9309) :824-830.
10Egan JM, Meneilly GS, Elahi D, et al. Effects 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes[J]. Am J Physiol Endocrinol Metab, 2003, 284(6): E1072-1079.
